HomeCompareNYMX vs SBUX

NYMX vs SBUX: Dividend Comparison 2026

NYMX yields 1000.50% · SBUX yields 2.84%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 NYMX wins by $18926778.64M in total portfolio value
10 years
NYMX
NYMX
● Live price
1000.50%
Share price
$0.20
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$18926778.81M
Annual income
$15,816,909,097,826.86
Full NYMX calculator →
SBUX
SBUX
● Live price
2.84%
Share price
$86.72
Annual div
$2.46
5Y div CAGR
48.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$167.0K
Annual income
$71,136.45
Full SBUX calculator →

Portfolio growth — NYMX vs SBUX

📍 NYMX pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodNYMXSBUX
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, NYMX + SBUX cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
NYMX pays
SBUX pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

NYMX
Annual income on $10K today (after 15% tax)
$85,042.52/yr
After 10yr DRIP, annual income (after tax)
$13,444,372,733,152.83/yr
SBUX
Annual income on $10K today (after 15% tax)
$241.12/yr
After 10yr DRIP, annual income (after tax)
$60,465.98/yr
At 15% tax rate, NYMX beats the other by $13,444,372,672,686.85/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of NYMX + SBUX for your $10,000?

NYMX: 50%SBUX: 50%
100% SBUX50/50100% NYMX
Portfolio after 10yr
$9463389.49M
Annual income
$7,908,454,584,481.66/yr
Blended yield
83.57%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on SBUX right now

NYMX
No analyst data
Altman Z
-1079.3
Piotroski
3/9
SBUX
Analyst Ratings
28
Buy
27
Hold
3
Sell
Consensus: Buy
Price Target
$104.00
+19.9% upside vs current
Range: $90.00 — $120.00
Altman Z
2.6
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

NYMX buys
0
SBUX buys
0
No recent congressional trades found for NYMX or SBUX in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricNYMXSBUX
Forward yield1000.50%2.84%
Annual dividend / share$2.00$2.46
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%48.3%
Portfolio after 10y$18926778.81M$167.0K
Annual income after 10y$15,816,909,097,826.86$71,136.45
Total dividends collected$18689176.71M$136.4K
Payment frequencyquarterlyquarterly
SectorStockConsumer Discretionary

Year-by-year: NYMX vs SBUX ($10,000, DRIP)

YearNYMX PortfolioNYMX Income/yrSBUX PortfolioSBUX Income/yrGap
1← crossover$110,750$100,050.03$11,121$420.68+$99.6KNYMX
2$1,154,067$1,035,564.75$12,548$648.40+$1.14MNYMX
3$11,319,965$10,085,113.06$14,440$1,013.98+$11.31MNYMX
4$104,563,222$92,450,859.72$17,068$1,617.30+$104.55MNYMX
5$909,989,518$798,106,870.01$20,912$2,649.52+$909.97MNYMX
6$7,465,033,954$6,491,345,169.85$26,875$4,499.29+$7465.01MNYMX
7$57,755,143,367$49,767,557,036.19$36,771$8,014.12+$57755.11MNYMX
8$421,647,934,611$359,849,931,208.39$54,542$15,197.11+$421647.88MNYMX
9$2,906,420,287,179$2,455,256,997,145.24$89,602$31,242.49+$2906420.20MNYMX
10$18,926,778,805,108$15,816,909,097,826.86$167,011$71,136.45+$18926778.64MNYMX

NYMX vs SBUX: Complete Analysis 2026

NYMXStock

Nymox Pharmaceutical Corporation, a biopharmaceutical company, engages in the research and development of drugs for the aging population in Canada, the United States, Europe, and internationally. Its lead drug candidate is Fexapotide Triflutate (NX-1207), which has completed Phase III clinical trials for the treatment of benign prostatic hyperplasia, and Phase II clinical trials for low grade localized prostate cancer, as well as is in preclinical studies for hepatocellular carcinoma. The company also develops and markets NicAlert and TobacAlert tests that use urine or saliva to detect use of tobacco products. In addition, it offers AlzheimAlert, a proprietary urine assay that aids physicians in the diagnosis of Alzheimer's disease, as well as researches and develops drug treatments for Alzheimer's disease. The company was founded in 1989 and is headquartered in Nassau, the Bahamas.

Full NYMX Calculator →

SBUXConsumer Discretionary

Starbucks Corporation, together with its subsidiaries, operates as a roaster, marketer, and retailer of specialty coffee worldwide. The company operates through three segments: North America, International, and Channel Development. Its stores offer coffee and tea beverages, roasted whole beans and ground coffees, single serve products, and ready-to-drink beverages; and various food products, such as pastries, breakfast sandwiches, and lunch items. The company also licenses its trademarks through licensed stores, and grocery and foodservice accounts. The company offers its products under the Starbucks, Teavana, Seattle's Best Coffee, Evolution Fresh, Ethos, Starbucks Reserve, and Princi brands. As of October 3, 2021, it operated 16,826 company-operated and licensed stores in North America; and 17,007 company-operated and licensed stores internationally. The company was founded in 1971 and is based in Seattle, Washington.

Full SBUX Calculator →
📬

Get this NYMX vs SBUX comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

NYMX vs SCHDNYMX vs JEPINYMX vs ONYMX vs KONYMX vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.